Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation. It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.
Company Valuation
From both historical and forecast perspectives, the stock is moderately underpriced compared to similar stocks.
Target Price
The average target price of AARD is 19 and suggests 406% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell